Artelo Biosciences, Inc. (ARTL) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Artelo Biosciences, Inc. (ARTL) trades at $0.7124 with AI Score 29/100 (Grade F). Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments that modulate the endocannabinoid system. Market cap: $2.48M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 1, 2026Analyst Coverage for ARTL: ARTL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARTL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ARTL: 1/3 scored disciplines lean bearish. Dominant signal: Momentum weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Artelo Biosciences, Inc. (ARTL) Healthcare & Pipeline Overview
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in endocannabinoid system modulation for conditions like cancer-related anorexia and PTSD. Their pipeline, featuring synthetic G protein-coupled receptor agonists and cannabidiol cocrystals, positions them in the competitive biotechnology sector with a focus on unmet medical needs.
What Is the Investment Thesis for ARTL?
Artelo Biosciences, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on modulating the endocannabinoid system offers potential for novel therapies targeting conditions with significant unmet needs. Key value drivers include the successful completion of clinical trials for ART27.13, ART12.11, and ART26.12, leading to potential regulatory approvals and commercialization. Upcoming catalysts include the progression of ART27.13 through its Phase 1b/2a clinical trial for cancer-related anorexia and the advancement of ART12.11 and ART26.12 into later-stage clinical development. The collaboration with Trinity College Dublin could also yield valuable insights and accelerate the development of ART27.13 for cancer cachexia. However, potential risks include clinical trial failures, regulatory hurdles, competition from other companies developing similar therapies, and the need for additional funding to support ongoing research and development activities. The company's small market capitalization of $2.48M reflects its early stage and the inherent uncertainties associated with biotechnology investments.
Based on FMP financials and quantitative analysis
ARTL Key Highlights
Artelo Biosciences is a clinical-stage biopharmaceutical company focused on modulating the endocannabinoid system.
- The company's lead product candidate, ART27.13, is in Phase 1b/2a clinical trial for anorexia associated with cancer.
- Artelo is also developing ART12.11 for inflammatory bowel disease and PTSD, and ART26.12 for prostate and breast cancer and PTSD.
- The company has a research collaboration with Trinity College Dublin to investigate ART27.13 for cancer cachexia.
- Artelo Biosciences has a small market capitalization of $2.48M, reflecting its early stage and growth potential.
Who Are ARTL's Competitors?
ARTL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARTL's Key Strengths?
Focus on the endocannabinoid system, a promising therapeutic target.
- Diverse product pipeline addressing multiple indications.
- Research collaboration with Trinity College Dublin.
- Experienced management team.
What Are ARTL's Weaknesses?
Limited financial resources.
- Small number of employees.
- Early-stage clinical development.
- Dependence on successful clinical trial outcomes.
What Could Drive ARTL Stock Higher?
Completion of Phase 1b/2a clinical trial for ART27.13 in cancer-related anorexia.
- Advancement of ART12.11 into later-stage clinical development for IBD and PTSD.
- Progress of ART26.12 in preclinical and clinical studies for prostate and breast cancer and PTSD.
- Results from research collaboration with Trinity College Dublin on ART27.13 for cancer cachexia.
What Are the Key Risks for ARTL?
Financial-distress signal — its Altman Z-Score of -19.30 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for ART27.13, ART12.11, or ART26.12.
- Regulatory delays or rejection of product candidates.
- Competition from other biotechnology and pharmaceutical companies.
- Need for additional funding to support research and development activities.
- Patent challenges or loss of intellectual property protection.
What Are the Growth Opportunities for ARTL?
- Advancement of ART27.13 for Cancer-Related Anorexia: ART27.13, a synthetic G protein-coupled receptor agonist, is currently in Phase 1b/2a clinical trials for treating anorexia associated with cancer. Successful completion of these trials and subsequent regulatory approval could provide a significant growth opportunity for Artelo. The market for anorexia treatments is substantial, with a growing need for effective therapies to improve the quality of life for cancer patients. The company's collaboration with Trinity College Dublin to investigate ART27.13 for cancer cachexia could further expand its potential applications.
- Development of ART12.11 for Inflammatory Bowel Disease and PTSD: ART12.11, a synthetic cannabidiol cocrystal, is being developed for the treatment of inflammatory bowel disease (IBD) and post-traumatic stress disorder (PTSD). Both IBD and PTSD represent significant market opportunities, with a large patient population and a growing demand for effective treatments. Successful development and commercialization of ART12.11 could generate substantial revenue for Artelo. The company's focus on a synthetic cannabidiol cocrystal may offer advantages over traditional cannabinoid-based therapies.
- Expansion of ART26.12 for Prostate and Breast Cancer: ART26.12, a fatty acid binding protein 5 inhibitor, is being explored as a potential treatment for prostate and breast cancer, as well as for PTSD. Prostate and breast cancer are two of the most prevalent cancers worldwide, representing a multi-billion dollar market opportunity. Successful development and commercialization of ART26.12 could provide a significant growth driver for Artelo. The company's focus on a fatty acid binding protein 5 inhibitor offers a novel approach to cancer treatment.
- Strategic Partnerships and Collaborations: Artelo can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional funding, expertise, and resources, enabling Artelo to expand its research and development efforts and reach a wider patient population. Collaborations could also help Artelo navigate the complex regulatory landscape and secure market access for its therapies.
- Expansion into New Therapeutic Areas: While Artelo's current pipeline focuses on cancer-related anorexia, IBD, PTSD, and prostate and breast cancer, the company could explore opportunities to expand into new therapeutic areas where modulation of the endocannabinoid system may offer potential benefits. This could include conditions such as chronic pain, neurodegenerative diseases, and autoimmune disorders. Expanding into new therapeutic areas would diversify Artelo's product portfolio and reduce its reliance on any single indication.
What Are ARTL's Competitive Advantages?
- Proprietary drug candidates targeting the endocannabinoid system.
- Patent protection for its product pipeline.
- Clinical data supporting the safety and efficacy of its therapies.
- Research collaborations with leading academic institutions.
What Does ARTL Do?
Artelo Biosciences, Inc., founded in 2011 and formerly known as Reactive Medical, Inc. until its name change in April 2017, is a clinical-stage biopharmaceutical company headquartered in Solana Beach, California. The company is dedicated to developing and commercializing treatments that modulate the endocannabinoid system, a crucial regulatory system in the human body. Artelo's approach involves creating innovative therapies for a range of conditions, including cancer-related anorexia, inflammatory bowel disease, post-traumatic stress disorder (PTSD), prostate cancer, and breast cancer. Their product pipeline features several promising candidates. ART27.13, a synthetic G protein-coupled receptor agonist, is currently in a Phase 1b/2a clinical trial for treating anorexia associated with cancer. ART12.11, a synthetic cannabidiol cocrystal, is being developed for the treatment of inflammatory bowel disease and PTSD. ART26.12, a fatty acid binding protein 5 inhibitor, is being explored as a potential treatment for prostate and breast cancer, as well as for PTSD. Artelo Biosciences also has a research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia, a wasting syndrome associated with cancer. Artelo's focus on the endocannabinoid system distinguishes it within the biotechnology industry. By targeting this system, Artelo aims to address unmet medical needs in various therapeutic areas, potentially offering new treatment options for patients with debilitating conditions. The company's clinical-stage pipeline and research collaborations reflect its commitment to advancing innovative therapies.
What Products and Services Does ARTL Offer?
- Develops and commercializes treatments to modulate the endocannabinoid system.
- Focuses on therapies for conditions like anorexia associated with cancer, inflammatory bowel disease, and PTSD.
- Develops synthetic G protein-coupled receptor agonists.
- Creates synthetic cannabidiol cocrystals.
- Develops fatty acid binding protein 5 inhibitors.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
How Does ARTL Make Money?
- Develops pharmaceutical products targeting the endocannabinoid system.
- Conducts research and development to identify and validate potential drug candidates.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing agreements, milestone payments, and royalties.
What Industry Does ARTL Operate In?
Artelo Biosciences operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation, with companies constantly seeking to develop new treatments for unmet medical needs. Artelo's focus on modulating the endocannabinoid system places it within a niche area of the biotechnology sector, targeting conditions such as cancer-related anorexia, inflammatory bowel disease, and PTSD. The company faces competition from other biotechnology and pharmaceutical companies developing therapies for these conditions, as well as from companies developing cannabinoid-based treatments.
Who Are ARTL's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel drug candidates.
- Patients suffering from conditions treatable by endocannabinoid system modulation.
- Healthcare providers prescribing Artelo's therapies.
- Research institutions collaborating with Artelo on drug development.
Financial Health
Artelo Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.30 places it in the distress zone, a signal of elevated financial risk.
Artelo Biosciences, Inc. (ARTL) Valuation Context
Valued at $2.48M, ARTL is classified as a micro-cap stock. Relative to its peer group, ARTL's quantitative score of 29/100 is below the peer average of 76/100.
Company Profile
Artelo Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Solana Beach, US. The company is led by CEO Gregory D. Gorgas. ARTL has traded publicly since 2019.
Forward Outlook
Wall Street analysts project Artelo Biosciences, Inc. revenue of about $0 for fiscal 2026, with EPS near $-9.84.
ARTL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Artelo's future prospects, with executives backing their own company during a critical phase.
- Community sentiment has shifted positively, driven by recent announcements regarding potential breakthroughs in their cannabis-based therapies.
- Increased interest in the biotech sector has led to a more favorable market perception, with investors looking for innovative solutions.
- Recent partnerships and collaborations have positioned Artelo to leverage its unique research, enhancing its credibility in the industry.
Bear Case
- Concerns over regulatory hurdles remain prevalent, as the cannabis sector often faces scrutiny that could impact Artelo's operations.
- Market sentiment has been mixed, with some investors wary of the high volatility and risks associated with biotech investments.
- Recent earnings reports have not met investor expectations, leading to skepticism about the company's short-term performance.
- Competitive pressures in the biotech space are intensifying, with emerging players potentially overshadowing Artelo's innovations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ARTL Latest News
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Jul 15, 2026
ARTL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARTL.
Price Targets
Wall Street price target analysis for ARTL.
ARTL MoonshotScore
What does this score mean?
The MoonshotScore rates ARTL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Gregory D. Gorgas
CEO
Gregory D. Gorgas serves as the CEO of Artelo Biosciences, Inc. He has extensive experience in the biopharmaceutical industry, with a background in finance, operations, and business development. Prior to joining Artelo, Mr. Gorgas held leadership positions at various biotechnology companies, where he was responsible for strategic planning, fundraising, and commercialization efforts. His expertise includes drug development, regulatory affairs, and market access.
Track Record: Under Mr. Gorgas's leadership, Artelo Biosciences has advanced its product pipeline through clinical trials and established research collaborations with leading academic institutions. He has overseen the company's fundraising efforts and guided its strategic direction. Key milestones include the initiation of Phase 1b/2a clinical trial for ART27.13 and the development of ART12.11 and ART26.12 for various indications.
What Investors Ask About Artelo Biosciences, Inc. (ARTL) — Healthcare
What does the AI Score mean for ARTL?
ARTL holds an AI Score of 29/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments that modulate the endocannabinoid system. Their pipeline includes drugs targeting anorexia …
What does Artelo Biosciences, Inc. do?
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments that modulate the endocannabinoid system. Their pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist in Phase 1b/2a clinical trials for anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for inflammatory bowel disease and PTSD; and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer and PTSD.
What do analysts say about ARTL stock?
As of 2026-06-01, analyst coverage of Artelo Biosciences, Inc. (ARTL) is limited due to its small market capitalization and early stage of development. Key valuation metrics are heavily dependent on the successful progression of its clinical trials. Investors should closely monitor the results of these trials, as well as any potential partnerships or collaborations.
What are the main risks for ARTL?
The main risks for Artelo Biosciences, Inc. include clinical trial failures, regulatory hurdles, competition from other biotechnology and pharmaceutical companies, and the need for additional funding. Clinical trial failures could significantly impact the company's valuation and future prospects. Regulatory delays or rejection of product candidates could also hinder its ability to commercialize its therapies.
What are the key factors to evaluate for ARTL?
Artelo Biosciences, Inc. (ARTL) holds an AI score of 29/100 (low). presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does ARTL data refresh on this page?
ARTL's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ARTL's recent stock price performance?
Artelo Biosciences, Inc. (ARTL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on the endocannabinoid system, a promising therapeutic target. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARTL overvalued or undervalued right now?
Artelo Biosciences, Inc. (ARTL) is loss-making, so its trailing P/E is negative (-0.1x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ARTL before investing?
Before investing in Artelo Biosciences, Inc. (ARTL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is for informational purposes only and does not constitute investment advice.